Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI +3.25%46 Gross Margin % is 27.06% as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued). Among 943 Drug Manufacturers companies, ODI Pharma AB ranks worse than 82.08% on this metric.
The historical rank and industry rank for ODI Pharma AB's Gross Margin % or its related term are showing as below:
XSAT:ODI'
s Gross Margin % Range Over the Past 10 Years
Min: -516.55 Med: -6.25 Max: 28.94
Current: 28.94
During the past 7 years, the highestGross Margin % of ODI Pharma AB was 28.94%. The lowest was -516.55%. And the median was -6.25%.
XSAT:ODI's Gross Margin % is ranked worse than 82.08% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs XSAT:ODI: 28.94
ODI Pharma AB had a gross margin of 27.06% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for ODI Pharma AB was 0.00% per year.
ODI Pharma AB (XSAT:ODI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ODI Pharma AB had a gross margin of 27.06% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ODI Pharma AB Gross Margin % Related Terms
ODI Pharma AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ODI Pharma AB (XSAT:ODI) has a Gross Margin % of 27.06% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #774 out of 943 companies in the Drug Manufacturers industry, placing it in the top 82.1%.
Is ODI Pharma AB's Gross Margin % too high?
ODI Pharma AB's current Gross Margin % is 27.06%. The Drug Manufacturers industry median Gross Margin % is 48.54. ODI Pharma AB's value of 27.06% is 44.3% below this industry median. Based on the distribution chart, ODI Pharma AB ranks #774 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #774 out of 943 companies for Gross Margin %. This places ODI Pharma AB in the lower half of its industry. The industry median Gross Margin % is 48.54. ODI Pharma AB's value of 27.06% is 44.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current Gross Margin % of 27.06% is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current Gross Margin % is 27.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current Gross Margin % is 27.06% and 44.3% below the Drug Manufacturers industry median of 48.54. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Gross Margin % is 27.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
Gross Margin %: 27.06%
GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
Industry Position: 44.3% below the Drug Manufacturers median (#774 of 943)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
